and in screening of blood products B 19 . '3 In the present work, we have studied the role of B 19 in the aetiopathogenesis of RA. For this purpose, samples from patients with early RA (onset of disease under one year) were analysed by using serological assay of B 19 antibodies and DNA amplification by PCR. As controls, patients with reactive arthritis (ReA) or other arthropathies and healthy blood donors were used. 25 We do not have a good explanation for the discrepancies between these two studies. In our study synovial biopsies were not studied, although this does not explain the different results, as Saal et al found B 19 in peripheral blood mononuclear cells of 15% of patients in all groups. The duration of RA of the patients described by Saal et al was approximately 1 1 years, whereas our patients suffered from recent onset RA. In our opinion it is preferable to study patients with disease duration as short as possible when the aetiological agent is being sought. We also studied by PCR samples taken from 9 patients with advanced RA [8 28 might be explained by the low prevalence of B 19 infection circulating in the community during our study.
Patients and methods

PATIENTS
According to our PCR and serological data, the association of B19 infection with RA is a rare phenomenon. Nevertheless, chronic B19 arthropathy should be kept in mind in the differential diagnosis of RA.7 Our data do not exclude the possibility of the virus persisting at the site of inflammation after acute infection, due to the small number of patients in our study who actually had chronic B19 arthropathy. The present findings do not support the involvement of B 19 in the aetiopathogenesis of RA. However, its role as a triggering factor in a genetically or otherwise predisposed host should not be ruled out. 
